Benserazide (HCl)

Drug #82

Benserazide (HCl) is used in pakinson's disease (mental disorder) with levodopa to reduce its side-effects by preventing peripheral breakdown of LEVODOPA, allowing reduced dosage and decreased side effects.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to Aromatic Amino Acid .

It belongs to L-amino acid decarboxylase inhibitor pharmacological group on the basis of mechanism of action and also classified in Antiparkinson Agents pharmacological group.

Molecular Weight: 293.7 · pK_a: · Solubility in Water: 1 in 3 · Solubility in Alcohol: 1 in 20 · Non-proprietary name: Benserazide (HCl).

Molecular structure of Benserazide (HCl)

Pharmacokinetics

Absorption: Benserazide (HCl) has an oral bioavailability is 70%.

Distribution: Benserazide (HCl) has a volume of distribution is . plasma protein binding is .

Elimination: it is metabolised via Rapid by liver & small intestine , plasma half-life is , renal excretion is 60% .

Indications

Benserazide (HCl) is primarily indicated in conditions like Parkinsonism.

Contraindications

Benserazide (HCl) is contraindicated in conditions like Psychosis, Narrow-angle glaucoma.

Dosage

Benserazide (HCl)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
0.595 mg/kg	0.595 mg/kg	Every 8h	PO	-
Paediatric Dosage (20kg)
0 – 0	—	—	—	Not Recommended in this Age Group
Neonatal Dosage (3kg)
0 – 0	—	—		Not recommended in his age group

Drug Interactions

Unknown1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Benserazide (HCl) in overdosage may give rise to further complications which include Dyskinesias , Fluctuating disability , Postural hypotension , Psychiatric disturbances .

Benserazide (HCl) produces potentially life-threatening effects which include Severe postural hypotension. Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of Benserazide (HCl) are Hypotension, Nausea, Vomiting, Cardiac arrhythmias, Chorea.

Benserazide (HCl) is known to cause more or less tolerable side effects which are usually transient. These include Elevated alkaline phosphatase, Elevated hepatic transaminases, Nausea, Vomiting .

Warnings / Precautions

Rapidly affects oxygenation and lung compliance and should be restricted to a highly supervised use in a clinical setting with immediate availability of clinicians experienced with intubation and ventilatory management of the premature infants. If transient episode of the bradycardia and decreased oxygen saturation occur, discontinue the dosing procedure and initiate measures to alleviate the condition, produces rapid improvements in lungs oxygenation and compliance that may require immediate reductions in ventilator settings and FiO2.

Interference in Pathology

Benserazide (HCl) may interfere in the diagnosis of Serum tests for bilirubin, catecholamines, creatinine, glucose and uric acid , Urine tests for amino acids, creatinine, creatinine clearance, estrogens & glucose , Urine tests for homogentisic acid, uric acid, ketones, vanillylmandelic acid & 5-OH ind acetic acid .

Available Brands

None recorded.

Storage Conditions

Benserazide (HCl) should be stored Powder.

Drug Classification

1.9.1 — Drugs used in parkinsonism